Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  • Attrezzature

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  • Attrezzature
  1. Pubblicazioni

Fast-acting approaches for treatment-resistant depression: real-world comparative effectiveness of Intranasal Esketamine versus accelerated rTMS

Articolo
Data di Pubblicazione:
2026
Citazione:
Fast-acting approaches for treatment-resistant depression: real-world comparative effectiveness of Intranasal Esketamine versus accelerated rTMS / Prato, M., Carminati, M., Frizzi, F., Verri, G., Tondello, M., Barbini, B., Colombo, C., Raffaella, Z.. - In: INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE. - ISSN 1365-1501. - 30:3(2026), pp. 256-263. [10.1080/13651501.2026.2642680]
Abstract:
Background: Treatment-Resistant Depression (TRD) often persists despite adequate pharmacotherapy. Intranasal Esketamine and accelerated repetitive Transcranial Magnetic Stimulation (aTMS) are rapid-acting options, but head-to-head comparisons remain limited. Methods: We conducted a retrospective study on TRD patients receiving either aTMS (n = 18) or Intranasal Esketamine (n = 22). Depression severity (Montgomery-Asberg Depression Rating Scale, MADRS) was assessed at baseline and 1, 3, and 6 months. Primary outcomes were response (≥50% MADRS reduction) and remission (MADRS <10). Longitudinal change was modelled with linear mixed-effects; moderators included clinical and demographics features. Results: At 1 month, aTMS showed higher response (72.2% vs 20%; p < 0.001) and remission (66.6% vs 10%; p = 0.0031) than Esketamine. Between-group differences were not significant at 3 months or 6 months. Mixed-effects models showed greater MADRS reduction with aTMS at 1 (p < 0.001) and 3 months (p = 0.007), but not at 6 months (p = 0.057). Psychiatric comorbidities were associated with greater improvement at 3 and 6 months within the Esketamine subgroup, with no analogous association in the aTMS subgroup. Conclusions: aTMS showed a stronger early antidepressant effect, but its advantage over esketamine progressively diminished and was no longer evident at six months. Prospective, well-powered comparative trials are required to validate these findings.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Prato, Michele; Carminati, Matteo; Frizzi, Filippo; Verri, Greta; Tondello, Mattia; Barbini, Barbara; Colombo, Cristina; Raffaella, Zanardi
Autori di Ateneo:
COLOMBO CRISTINA ANNA
Link alla scheda completa:
https://iris.unisr.it/handle/20.500.11768/208058
Pubblicato in:
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
Journal
  • Dati Generali

Dati Generali

URL

https://www.tandfonline.com/doi/full/10.1080/13651501.2026.2642680
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.10.1.0